Orphan Therapeutics Accelerator Announces Foundational Partnerships
Founding Members Chiesi, BIAL Lead Initial Funding;
Landmark Bio, Uncommon Cures Join Clinical Development Network;
DVLP Medicines, Vibe Bio to Provide Integrated AI-based Solutions
Biopharma BD&L: the tsunami is upon us
Pharma’s business development and licensing (BD&L) teams are at the forefront of identifying new science to support their company’s future. As the biopharma industry navigates an increasingly complex marketplace, traditional approaches to identifying and evaluating potential drug candidates are showing signs of strain.
